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Neus Ferrer-Miralles1,2,3 and Antonio Villaverde1,2,3*Escherichia coli has been the pioneering host for recom-
binant protein production, since the original recombinant
DNA procedures were developed using its genetic mater-
ial and infecting bacteriophages. As a consequence, and
because of the accumulated know-how on E. coli genetics
and physiology and the increasing number of tools for
genetic engineering adapted to this bacterium, E. coli is
the preferred host when attempting the production of a
new protein. Also, it is still the first choice for protein pro-
duction at laboratory and industrial scales for an import-
ant number of proteins, being fast growth and simple
culture procedures critical issues. When searching for an
ideal system for protein production, this bacterial species
is clearly far from offering, in generic terms, optimal
conditions for protein production and downstream.
Plasmid loss and antibiotic-based maintenance, un-
desired chemical inducers of gene expression, plasmid/
protein-mediated metabolic burden and stress responses,
lack of post-translational modifications (including the in-
ability to form disulphide bonds), none or poor secretion,
protein aggregation and proteolytic digestion, endotoxin
contamination and complex downstream are among the
main obstacles encountered during protein production in
E. coli. In the pharmaceutical scenario, proper protein
glycosylation is often requested and simplest purification
procedures become highly desirable when pursuing
cost-effective bioproduction. In this context, the yeast
Sacharomyces cerevisae, diverse mammalian cell lines,
insect cells and whole plant and animals (as transgenic
systems) are being incorporated to the protein produc-
tion scenario [1], and many of these products have been
already approved for use as protein drugs [2]. Other
(less conventional) yeast species and a more limited num-
ber of species of filamentous fungi [3], molds [4], moss [5],
algae [6] and protozoa [7] are also under development as* Correspondence: antoni.villaverde@uab.cat
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article, unless otherwise stated.potential suppliers of recombinant proteins. The engin-
eering of such systems could represent a promising way
to the cost effective production of high quality protein
versions that biotechnology and biomedical industries
are steadily demanding. The potential and versatility of
these platforms as protein producers or in general, as cell
factories for added value products such as chemicals,
amino acids or vitamins has been stressed in recent ex-
perimental reports or reviews [8-17]. Despite this, it must
be noted that adapting large-scale production processes to
the biological complexity of some of these systems might
represent, in some cases, an unaffordable task.
From a different angle, bacterial hosts others than E. coli
are attracting attention as cell factories due to their
metabolic diversity and biosynthetic potential derived
from adaptation to extremely diverse environments. The
most important bacterial groups explored as cell factories
for recombinant proteins and their associated potential-
ities are summarized in Table 1. The implementation of
lactic acid bacteria as a routine cell factory expands their
applications from conventional food microbiology [18-21]
to protein production and also protein drug display and
delivery [22-29], taking advantage of the generically
recognized as safe (GRAS) features of this platform. Im-
proved solubility in halophillic and cold-adapted bacteria,
enhanced secretion in acid lactic bacteria and in general in
endotoxin-free gram-positive species and post-translational
modifications in mycobacteria among others are highly
appealing properties in protein production, that can be of
special value for specific difficult-to-express proteins.
While exhibiting most of the above mentioned limitations
linked to prokaryotic-based production, exploring bacter-
ial species other than E. coli should be not abandoned but
fully supported as it will not only expand the current cata-
logue of cell factories but also offer novel process oppor-
tunities in easily cultivable/scalable systems that might
pose, in generic terms, less methodological issues than
unconventional protein production systems [30].BioMed Central Ltd. This is an Open Access article distributed under the terms
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Table 1 The most important bacterial groups explored as cell factories for recombinant protein production
Host Main features Reviewsa Main bacterial Species Case proteins References
Proteobacteria Caulobacteria Easy purification of
secreted RSaA fusions
[31,32] Caulobacter crescentus Hematopoietic necrosis virus
capsid proteins
[33]
β-1,4-glycanase [34]
Phototrophic
bacteria
High production of
membrane proteins
[35] Rodhobacter sphaeroides Membrane proteins [35]
Cold adapted
bacteria
Improved protein folding [36,37] Pseudoalteromonas
haloplanktis
3H6 Fab [38]
Human nerve growth factor [39]
Shewanella sp. strain
Ac10
β-Lactamase, peptidases, glucosidase [40]
Pseudomonads Efficient secretion [41] Pseudomonas
fluorescens
Human granulocyte colony-
stimulating factor
[42]
Pseudomonas putida Single chain Fv fragments [43]
Pseudomonas
aeruginosa
Penicillin G acylase [44]
Halophilic
bacteria
Solubility favored [45] Halomonas elongata β-Lactamase [45]
Chromohalobacter
salexigens
Nucleoside diphosphate kinase [46]
Actinobacteria Streptomycetes Efficient secretion [47,48] Streptomyces lividans M. tuberculosis antigens [49]
Streptomyces griseus Trypsin [50]
Nocardia Efficient secretion [48] Nocardia lactamdurans Lysine-6-aminotransferase [51]
Mycobacteria Posttranslational
modifications
[52] Mycobacterium
smegmatis
Hsp65-hIL-2 fusion protein [53]
Mycobacterial proteins [54]
Coryneform
bacteria
High-level production
and secretion; GRAS
[48,55] Corynebacterium
glutamicum
Protein-glutaminase [56]
Corynebacterium
ammoniagenes
Pro-transglutaminase [57]
Brevibacterium
lactofermentum
Cellulases [58]
Firmicutes Bacilli High-level production
and secretion
[59-64] Bacillus subtilis β-Galactosidase [65]
Bacillus brevis Disulfide isomerase [66,67]
Bacillus megaterium Antibodies [68]
Bacillus licheniformis Subtilisin [69]
Bacillus
amyloliquefaciens
Amylases [70]
Lactic acid
bacteria
Secretion; GRAS [22-24,71] Lactococcus lactis Fibronectin-binding protein A,
internalin A, GroEL
[72,73]
Lactobacillus plantarum β-Galactosidase [74]
Lactobacillus casei VP2-VP3 fusion protein of infectious
pancreatic necrosis virus
[75]
Lactobacillus reuteri Pediocin PA-1 [76]
Lactobacillus gasseri CC chemokines [77]
aGeneric reviews about the biological platform or about specific tools for protein production.
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synthesis by microbes [78] and assisted by expanding
systems metabolic engineering and synthetic biology
tools [79], industrial biotechnology should desirablyfind within the prokaryotic world, a growing spectrum
of alternatives to eukaryotic cell factories, that apart
from easy and cost-effective cultivation provide unex-
pectedly high metabolic versatility and biosafety of their
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extent, it is solving some of the main issues posed by
E. coli as traditional producer or recombinant proteins.
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